focus -WSS

focus

author：focus 2025-10-01 02:27:57 - browse：94642

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Three trends to watch in biotech in 2024

WSS

Virtual care provider acquires bankrupt Pear's prescription apps

SEC charges former device maker CEO with $41 million fraud

AstraZeneca chief proposes a novel edit to the drug pricing bill

'Make People Better': The CRISPR babies story you probably don't know

Bristol Myers buys into radiopharmaceuticals with RayzeBio

What drug price negotiations mean for Medicare Part D

focus

focus

leisure time

Supreme Court strikes down use of affirmative action

Humana sues Biden admin over Medicare Advantage audit rule

Activists slam private health insurers over coverage restrictions

Carvykti CAR

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The 10 drugs up first for Medicare price negotiation

In Memoriam: Notable people who died in 2023

ALS advocates say criticism of new drugs misses bigger picture

State Dept. review finds Biden bears some blame for Afghanistan failures

HCA sued by state AG for quality issues at Mission Health

leisure time

Medicaid rebukes states for mistakenly disenrolling children

Readout Newsletter: The latest on Moderna, Apellis, and Merck

What drug price negotiations mean for Medicare Part D

Drinking less cuts risk of oral cavity, esophageal cancer: Report

House transparency, PBM reform bill gains bipartisan support

The 10 drugs up first for Medicare price negotiation

hotspot

leisure time

hotspot

Wikipedia